A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC).

dc.contributor.author	Curigliano, G
dc.contributor.author	Loibl, S
dc.contributor.author	Müller, V
dc.contributor.author	Pivot, X
dc.contributor.author	Wardley, Andrew M
dc.contributor.author	Cameron, D
dc.date.accessioned	2017-05-02T19:42:42Z
dc.date.available	2017-05-02T19:42:42Z
dc.date.issued	2016-10-01
dc.identifier.citation	A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC). 2016, 27(suppl 6):312TiP Annals of Oncology	en
dc.identifier.issn	0923-7534
dc.identifier.issn	1569-8041
dc.identifier.doi	10.1093/annonc/mdw365.91
dc.identifier.uri	http://hdl.handle.net/10541/620305
dc.language.iso	en	en
dc.relation.url	https://academic.oup.com/annonc/article/2799051/A	en
dc.rights	Archived with thanks to Annals of Oncology	en
dc.title	A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC).	en
dc.type	Meetings and Proceedings	en
dc.contributor.department	Drug Development, Istituto Europeo di Oncologia, Milan, Italy	en
dc.identifier.journal	Annals of Oncology	en